AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$MGX

Wein Matthew sold $415 of MGX

Wein Matthew (See Remarks) sold 358 shares of Metagenomi Therapeutics, Inc. (MGX) at $1.16 on 2026-09-08.

Original reporting
SEC EDGAR · Wein Matthew
Published Sep 10, 2026, 7:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 8:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MGX
Neutral
high confidence
Mentioned
$MGX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MGXNeutralLow
01

Why it matters

The sale is minor and unlikely to affect MGX stock price.

02

Market read

Low relevance; small insider sell with minimal market impact.

03

What to watch

Potential upcoming dilution or secondary offerings not disclosed.

Relevance 3/10Novelty 4/10Timing: Filed Sep 10 2026 (SEC Form 4)

Background

SEC Form 4 filing discloses insider transactions; required for transparency.

Company-level read

Ticker impact

$MGXNeutralHigh confidence
Context

Insider officer Wein Matthew sold 358 shares for $414.71 on Sep 8, 2026, reducing his holdings to 126,133 shares.

Expected impact

No significant impact expected.

Evidence & confidence

The transaction size ($415) is trivial relative to market cap and typical trading volume.

Market effects

Sector

None; the sale does not affect the biotech sector broadly.

Regional

None; limited to the company.

Global

None

Counterpoint

What could challenge this read

Even small insider sells can signal concerns; monitor future filings for pattern.

Key entities

  • Company
    Metagenomi Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker MGX.

  • Officer
    Wein Matthew

    Officer of Metagenomi who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MGX insider trading history →

Related articles

AUG 10
$MGXMed

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Metagenomi Therapeutics, Inc. (MGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in

SEC EDGAR 8-K4 min
OCT 23
$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).

SEC EDGAR1 min